Drug and xenobiotic biotransformation in the blood–brain barrier: A neglected issue

Frontiers in Cellular Neuroscience

Volumn 8, Issue OCT, 2014, Pages

  Agúndez, José A G ^a,b   Jiménez Jiménez, Félix J ^c   Alonso Navarro, Hortensia ^c   García Martín, Elena ^a,b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Hospital Universitario del Sureste de Madrid   (Spain)

Author keywords

Blood brain barrier; CNS drug; Drug metabolizing enzymes; Drug response; Expression profiling

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; ACYLTRANSFERASE; AMINE OXIDASE (FLAVIN CONTAINING); AMINOPEPTIDASE; AMODIAQUINE; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CATECHOL METHYLTRANSFERASE; CHOLINESTERASE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; MELATONIN; NARCOTIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROCARBAZINE; PROTEINASE; SULFOTRANSFERASE; UNINDEXED DRUG; XENOBIOTIC AGENT;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; DRUG CONCENTRATION; DRUG RESPONSE; DRUG TRANSFORMATION; DURA MATER; ENZYME ACTIVITY; ENZYME REGULATION; EPILEPSY; GENE EXPRESSION PROFILING; GLIA CELL; GLIOMA; HUMAN; LIPOPHILICITY; MICROGLIA; PROTEIN EXPRESSION; XENOBIOTIC METABOLISM;

EID: 84907964835     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00335     Document Type: Article

References (48)

1. Agúndez, J. A., and García-Martin, E. (2014). “Importance of CYP2D6 genotype/activity testing and applications,” in CYP2D6: Genetics, Pharmacology and Clinical Relevance, ed. P. Baumann (London: Future Medicine Ltd.), 118–133.
2. Agundez, J. A., Garcia-Martin, E., Alonso-Navarro, H., and Jimenez-Jimenez, F. J. (2013). Anti-Parkinson’s disease drugs and pharmacogenetic considerations. Expert Opin. Drug Metab. Toxicol. 9, 859–874.
3. Agundez, J. A., Garcia-Martin, E., and Martinez, C. (2009). Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol. 5, 607–620.
4. Aiba, I., Yamasaki, T., Shinki, T., Izumi, S., Yamamoto, K., Yamada, S., et al. (2006). Characterization of rat and human CYP2J enzymes asVitamin D 25-hydroxylases. Steroids 71, 849–856.
5. Bournique, B., and Lemarie, A. (2002). Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab. Dispos. 30, 1149–1152.
6. Choudhary, D., Jansson, I., Stoilov, I., Sarfarazi, M., and Schenkman, J. B. (2004). Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab. Dispos. 32, 840–847.
7. Dauchy, S., Dutheil, F., Weaver, R. J., Chassoux, F., Daumas-Duport, C., Couraud, P. O., et al. (2008). ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J. Neurochem. 107, 1518–1528.
8. Decleves, X., Jacob, A., Yousif, S., Shawahna, R., Potin, S., and Scherrmann, J. M. (2011). Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr. Drug Metab. 12, 732–741.
9. de Leon, J. (2003). Glucuronidation enzymes, genes and psychiatry. Int. J. Neuropsychopharmacol. 6, 57–72.
10. Dubey, R. K., Jackson, E. K., Gillespie, D. G., Rosselli, M., Barchiesi, F., Krust, A., et al. (2005). Cytochromes 1A1/1B1- and catechol-O-methyltransferase-derived metabolites mediate estradiol-induced antimitogenesis in human cardiac fibroblast. J. Clin. Endocrinol. Metab. 90, 247–255.
11. Dutheil, F., Dauchy, S., Diry, M., Sazdovitch, V., Cloarec, O., Mellottee, L., et al. (2009). Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab. Dispos. 37, 1528–1538.
12. Evans, W. E., and Relling, M. V. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491.
13. Garcia-Martin, E., Ayuso, P., Martinez, C., Blanca, M., and Agundez, J. A. (2009). Histamine pharmacogenomics. Pharmacogenomics 10, 867–883.
14. Garcia-Martin, E., Canto, G., and Agundez, J. A. (2013). Metabolic considerations of drugs in the treatment of allergic diseases. Expert Opin. Drug Metab. Toxicol. 9, 1437–1452.
15. Goldmann, E. E. (1913). “Vitalfärbung am zentralnervensystem: Beitrag zur Physio-Pathologie des Plexus Chorioideus und der Hirnhäute,” in Abhandlun-gen Preussischen Akademie der Wissenschaften Physikalisch Mathematisch klasse, Vol. 1 (Berlin: Königl. Akademie der Wissenschaften), 1–60.
16. Granberg, L., Ostergren, A., Brandt, I., and Brittebo, E. B. (2003). CYP1A1 and CYP1B1 in blood-brain interfaces: CYP1A1-dependent bioactivation of 7,12-dimethylbenz(a)anthracene in endothelial cells. Drug Metab. Dispos. 31, 259–265.
17. Haseloff, R. F., Krause, E., Bigl, M., Mikoteit, K., Stanimirovic, D., and Blasig, I. E. (2006). Differential protein expression in brain capillary endothe-lial cells induced by hypoxia and posthypoxic reoxygenation. Proteomics 6, 1803–1809.
18. Hashizume, T., Imaoka, S., Mise, M., Terauchi, Y., Fujii, T., Miyazaki, H., et al. (2002). Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J. Pharm. Exp. Ther. 300, 298–304.
19. Kang, M. J., Kim, H. G., Kim, J. S., Oh do, G., Um, Y. J., Seo, C. S., et al. (2013). The effect of gut microbiota on drug metabolism. Expert Opin. Drug Metab. Toxicol. 9, 1295–1308.
20. Khokhar, J.Y., and Tyndale, R. F. (2011). Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects. Neuropsychopharmacology 36, 692–700.
21. Lee, S. S., Jeong, H. E., Liu, K. H., Ryu, J. Y., Moon, T., Yoon, C. N., et al. (2005). Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet. Genomics 15, 105–113.
22. Li, D. N., Seidel, A., Pritchard, M. P., Wolf, C. R., and Friedberg, T. (2000). Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 10, 343–353.
23. Li, X. Q., Bjorkman, A., Andersson, T. B., Ridderstrom, M., and Masimirembwa, C. M.(2002). Amodiaquine clearanceand itsmetabolismtoN-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 300, 399–407.
24. Ma, X., Idle, J. R., Krausz, K. W., and Gonzalez, F. J. (2005). Metabolism of melatonin by human cytochromes p450. Drug Metab. Dispos. 33, 489–494.
25. Martinez, C., Galvan, S., Garcia-Martin, E., Ramos, M. I., Gutierrez-Martin, Y., and Agundez, J. A. (2010). Variability in ethanol biodisposition in whites is modulated by polymorphisms in the ADH1B and ADH1C genes. Hepatology 51, 491–500.
26. Mast, N., Norcross, R., Andersson, U., Shou, M., Nakayama, K., Bjorkhem, I., et al. (2003). Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry 42, 14284–14292.
27. Matsumoto, S., Hirama, T., Kim, H. J., Nagata, K., and Yamazoe, Y. (2003). In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver. Xenobiotica 33, 615–623.
28. Matsumoto, S., Hirama, T., Matsubara, T., Nagata, K., and Yamazoe, Y. (2002). Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab. Dispos. 30, 1240–1245.
29. Minn, A., Ghersi-Egea, J. F., Perrin, R., Leininger, B., and Siest, G. (1991). Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res. Brain Res. Rev. 16, 65–82.
30. Nishimura, M., Yaguti, H., Yoshitsugu, H., Naito, S., and Satoh, T. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123, 369–375.
31. Pardridge, W. M. (2012). Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 32, 1959–1972.
32. Patterson, L. H., and Murray, G. I. (2002). Tumour cytochrome P450 and drug activation. Curr. Pharm. Des. 8, 1335–1347.
33. Pereira de Sousa, I., and Bernkop-Schnurch, A. (2014). Pre-systemic metabolism of orally administered drugs and strategies to overcome it. J. Control. Release 192C, 301–309.
34. Relling, M. V., and Klein, T. E. (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464–467.
35. Restrepo, J. G., Garcia-Martin, E., Martinez, C., and Agundez, J. A. (2009). Polymorphic drug metabolism in anaesthesia. Curr. Drug Metab. 10, 236–246.
36. Schuster, I. (2011). Cytochromes P450 are essential players in the vitamin D signaling system. Biochim. Biophys. Acta 1814, 186–199.
37. Shang, W., Liu, W. H., Zhao, X. H., Sun, Q. J., Bi, J. Z., and Chi, Z. F. (2008). Expressions of glutathione S-transferase alpha, mu, and pi in brains of medically intractable epileptic patients. BMC Neurosci. 9:67. doi: 10.1186/1471-2202-9-67
38. Shawahna, R., Decleves, X., and Scherrmann, J. M. (2013). Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes. Curr. Drug Metab. 14, 120–136.
39. Shawahna, R., Uchida, Y., Decleves, X., Ohtsuki, S., Yousif, S., Dauchy, S., et al. (2011). Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm. 8, 1332–1341.
40. Shimada, T., Gillam, E. M., Sutter, T. R., Strickland, P. T., Guengerich, F. P., and Yamazaki, H. (1997). Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab. Dispos. 25, 617–622.
41. Shimada, T., Watanabe, J., Kawajiri, K., Sutter, T. R., Guengerich, F. P., Gillam, E. M., et al. (1999). Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20, 1607–1613.
42. Spink, D. C., Spink, B. C., Zhuo, X., Hussain, M. M., Gierthy, J. F., and Ding, X. (2000). NADPH- and hydroperoxide-supported 17beta-estradiol hydroxylation catalyzed by a variant form (432L, 453S) of human cytochrome P450 1B1. J. Steroid Biochem. Mol. Biol. 74, 11–18.
43. Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-vander Zee, A. H., Mulder, H., et al. (2011). Pharmacogenetics: from bench to byte–an update of guidelines. Clin. Pharmacol. Ther. 89, 662–673.
44. Ueno, M. (2009). Mechanisms of the penetration of blood-borne substances into the brain. Curr. Neuropharmacol. 7, 142–149.
45. Wang, X., Hawkins, B. T., and Miller, D. S. (2011). Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J. 25, 644–652.
46. Zakhari, S. (2006). Overview: how is alcohol metabolized by the body? Alcohol Res. Health 29, 245–254.
47. Zhang, Y., Gaikwad, N. W., Olson, K., Zahid, M., Cavalieri, E. L., and Rogan, E. G. (2007). Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metab. Clin. Exp. 56, 887–894.
48. Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44, 279–304.